Related Experiment Video

Updated: May 30, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Does lipoprotein (a) level have a predictive value in restenosis after coronary stenting?

Alireza Khosravi1, Masoud Pourmoghaddas, Fereshteh Ziaie

  • 1Isfahan Hypertension Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

International Journal of Preventive Medicine
|August 4, 2011
PubMed

Insights

High fasting blood glucose, a marker of diabetes mellitus, is linked to restenosis after coronary stenting. Managing diabetes may improve outcomes following this procedure.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Metabolic Disorders

Background:

  • Coronary artery disease (CAD) risk factors include lipid disorders, lipoproteins, diabetes mellitus, and hypertension.
  • The role of these factors, especially lipoprotein (a) [Lp (a)], in restenosis after coronary stenting remains unclear.
  • Bare Metal Stent (BMS) implantation is a common intervention for CAD.

Purpose of the Study:

  • To investigate the predictive role of lipid disorders, lipoproteins (including Lp (a)), diabetes mellitus, and hypertension in restenosis after coronary stenting with BMS.
  • To identify modifiable risk factors for restenosis.

Main Methods:

  • A prospective study involving 170 patients undergoing coronary artery stenting with BMS.
  • Coronary angiography performed at 6-month follow-up in 128 patients to assess restenosis.
  • Comparison of clinical and biochemical characteristics between patients with and without restenosis.

Main Results:

  • Restenosis occurred in 35.9% of patients (46 out of 128).
  • Significantly higher fasting blood glucose (FBG) levels were observed in patients with restenosis (102.3 ± 39 mg/dl) compared to those without (84.5 ± 28.9 mg/dl).
  • Lipoprotein (a) [Lp (a)] levels and other biochemical/clinical variables showed no significant correlation with restenosis.

Conclusions:

  • Lipoproteins and lipids may not be primary drivers of restenosis after coronary stenting.
  • Effective management of diabetes mellitus, indicated by FBG control, may enhance prognosis following elective coronary stenting.
Abstract

Keywords:
DiabetesLipidLipoprotein (a)RestenosisStent

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...